Glucocorticoids for Post-operative Patients With Acute Type A Aortic Dissection (The GLAD Trial)
Assessment of the Efficacy of Glucocorticoids in Improving Post-operative Organ Dysfunction in Patients With Acute Type A Aortic Dissection(GLAD): a Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200000
- Zhongshan hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Informed consent
- Age above 18 years old (including 18 years old), regardless of gender;
- Confirmed type A aortic dissection with computer tomography and received surgical intervention
- Life expectancy > 3 days after surgery
Exclusion Criteria:
- History of cardiac surgery within the past 3 months or possible iatrogenic aortic dissection
- Bacterial or fungal infection in the past 30 days
- Glucocorticoid or any other anti-inflammatory drug usage in the past 14 days
- Allergic to glucocorticoid
- Pregnant
- Implantation of ICD or permanent pacemaker
- Patients diagnosed with malignant tumor undergoing chemotherapy and immunotherapy.
- Patients with pre-operative severe liver dysfunction (CTP grade C)
- Patients with pre-operative renal insufficiency (patients receiving renal replacement therapy before surgery)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Control Group
|
|
|
Experimental: Glucocorticoid group
|
All eligible patients randomised to the glucocorticoid group will receive intravenous Methylprednisolone for 3 days after surgery.
The dosage is 2mg/kg/d on post-operative day 1, 1mg/kg/d on post-operative day 2, and 0.5mg/kg/d on post-operative day 3.
The daily dosage will be administered with two injections (12h interval).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Amplitude of variation of SOFA score on post-operative day 4 compared to baseline
Time Frame: Within 4 days on admission to CSICU
|
Within 4 days on admission to CSICU
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
In-hospital mortality
Time Frame: Up to 30 days
|
Up to 30 days
|
|
|
Duration of ICU stay
Time Frame: Up to 30 days
|
Up to 30 days
|
|
|
Duration of mechanical ventilation
Time Frame: Up to 30 days
|
Up to 30 days
|
|
|
Duration of hospital stay
Time Frame: Up to 30 days
|
Up to 30 days
|
|
|
The proportion of patients receiving RRT
Time Frame: Up to 30 days
|
Use of Renal Replacement Therapy(RRT)
|
Up to 30 days
|
|
The duration of RRT will be compared between two groups.
Time Frame: Up to 30 days
|
Use of Renal Replacement Therapy(RRT)
|
Up to 30 days
|
|
Incidence of Tracheostomy
Time Frame: Up to 30 days
|
Up to 30 days
|
|
|
Incidence of Post-operative infection
Time Frame: Up to 30 days
|
Up to 30 days
|
|
|
Changes in Inflammation markers
Time Frame: Within 3 days on admission to CSICU
|
Inflammation markers include IL-1, IL2R, IL-6 and TNFa
|
Within 3 days on admission to CSICU
|
|
Rate of Composite outcome
Time Frame: Up to 30 days
|
In-hospital mortality or Duration of ICU stay longer than 30 days or The need for tracheostomy
|
Up to 30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Zhe Luo, MD, PhD, Fudan University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Aneurysm
- Aortic Diseases
- Dissection, Blood Vessel
- Acute Aortic Syndrome
- Aortic Dissection
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
Other Study ID Numbers
Other Study ID Numbers
- B2022-030R2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.